PL2158316T3 - Ekspresja genowa oraz ból - Google Patents

Ekspresja genowa oraz ból

Info

Publication number
PL2158316T3
PL2158316T3 PL08755344T PL08755344T PL2158316T3 PL 2158316 T3 PL2158316 T3 PL 2158316T3 PL 08755344 T PL08755344 T PL 08755344T PL 08755344 T PL08755344 T PL 08755344T PL 2158316 T3 PL2158316 T3 PL 2158316T3
Authority
PL
Poland
Prior art keywords
pain
gene expression
gene
expression
Prior art date
Application number
PL08755344T
Other languages
English (en)
Inventor
Julien Mamet
Original Assignee
Adynxx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx Inc filed Critical Adynxx Inc
Publication of PL2158316T3 publication Critical patent/PL2158316T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PL08755344T 2007-05-11 2008-05-12 Ekspresja genowa oraz ból PL2158316T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758307P 2007-05-11 2007-05-11
PCT/US2008/063471 WO2008141308A2 (en) 2007-05-11 2008-05-12 Gene expression and pain
EP08755344.2A EP2158316B1 (en) 2007-05-11 2008-05-12 Gene expression and pain

Publications (1)

Publication Number Publication Date
PL2158316T3 true PL2158316T3 (pl) 2015-10-30

Family

ID=40002879

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08755344T PL2158316T3 (pl) 2007-05-11 2008-05-12 Ekspresja genowa oraz ból

Country Status (13)

Country Link
US (5) US7943591B2 (pl)
EP (3) EP2818550B1 (pl)
JP (5) JP5646320B2 (pl)
AU (1) AU2008251320B2 (pl)
CA (1) CA2723672C (pl)
DK (1) DK2158316T3 (pl)
ES (2) ES2542511T3 (pl)
HR (1) HRP20150759T1 (pl)
HU (1) HUE025701T2 (pl)
PL (1) PL2158316T3 (pl)
PT (1) PT2158316E (pl)
SI (1) SI2158316T1 (pl)
WO (1) WO2008141308A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150759T1 (hr) * 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
WO2011029092A1 (en) 2009-09-04 2011-03-10 University Of Miami Klf family members regulate intrinsic axon regeneration ability
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
US20130071444A1 (en) 2011-09-16 2013-03-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Amphiphilic Cationic Polymers and Methods of Use Thereof
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
CN104487096B (zh) * 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
EP2872147B1 (en) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Method for making chiral oligonucleotides
GB201310853D0 (en) * 2013-06-18 2013-07-31 Ucb Pharma Sa Method
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
CA2936712A1 (en) 2014-01-16 2015-07-23 Meena Chiral design
CA2957250A1 (en) * 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
EP3348637B1 (en) * 2015-09-09 2022-03-09 AnGes, Inc. Chimeric decoy
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20260078376A1 (en) * 2022-08-26 2026-03-19 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
CA2168245A1 (en) 1993-07-29 1995-02-09 C. Anthony Hunt Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
WO1995011687A1 (en) 1993-10-29 1995-05-04 Dzau Victor J Therapeutic use of cis-element decoys in vivo
AU3881095A (en) 1994-11-17 1996-06-17 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
WO1996029433A1 (en) 1995-03-23 1996-09-26 Research Foundation Of State University Of New York Rest protein and dna
US6004813A (en) 1995-05-11 1999-12-21 Applied Research Systems Ars Holding N.V. Il-6 activity inhibitor
EP0824918B1 (en) 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6316190B1 (en) 1996-05-20 2001-11-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
EP1008352A4 (en) 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
AU9692198A (en) 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
YU75600A (sh) 1998-06-02 2004-03-12 Glaxo Group Limited Upotreba polipeptida faktora transkripcije e
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6423493B1 (en) 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6008048A (en) 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
AU761136B2 (en) 1998-12-23 2003-05-29 Genentech Inc. Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1344536A4 (en) 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd METHOD FOR REGULATING THE EFFECT OF THE EXPRESSION PRODUCT OF A GENE TRANSFERRED IN A LIVING BODY
US20020137715A1 (en) 2001-01-03 2002-09-26 Alain Mauviel Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
WO2002057480A2 (en) 2001-01-22 2002-07-25 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
ATE390938T1 (de) 2001-02-20 2008-04-15 Anges Mg Inc Topische anwendung eines nf-kb decoys zur behandlung atopischer dermatitis
AU2002254132A1 (en) 2001-03-06 2002-09-19 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
AU2003212898B2 (en) 2002-02-01 2008-10-02 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
KR100874798B1 (ko) 2002-04-26 2008-12-19 이인규 전사시 ｄｎａ 결합부위를 포함하는 원형의 아령형 디코이올리고뉴클레오티드
DE10242319A1 (de) 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
DE10257421A1 (de) 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
KR20140027554A (ko) 2002-12-09 2014-03-06 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
JP2007528707A (ja) 2003-06-30 2007-10-18 マサチューセッツ インスティテュート オブ テクノロジー 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子
US20080233644A1 (en) * 2003-09-12 2008-09-25 Helen Fillmore Chimeric Transcription Factor Decoy Oligonucleotides
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060293264A1 (en) 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
EP1799271A4 (en) 2004-09-21 2010-05-05 Anesiva Inc DISPOSAL OF POLYNUCLEOTIDES
BRPI0516177B8 (pt) 2004-09-28 2021-05-25 Quark Biotech Inc oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53
CA2583576A1 (en) 2004-10-22 2006-04-27 Anges Mg, Inc. Chimera (double) decoy
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) * 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
US7680060B2 (en) * 2005-03-08 2010-03-16 Cisco Technology, Inc. Transferring state information in a network
ATE524546T1 (de) 2005-03-25 2011-09-15 Medtronic Inc Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
EP3827841B1 (en) 2006-10-09 2024-04-03 Neurofluidics, Inc. Cerebrospinal fluid purification system
EP2146691A2 (en) 2007-04-17 2010-01-27 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
SI2605794T1 (sl) 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
WO2012177906A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
CN103781484A (zh) 2011-07-20 2014-05-07 赫思公司 治疗疼痛的方法
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
BR112014028654A2 (pt) 2012-05-18 2017-10-10 Replicor Inc composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
WO2017151644A1 (en) 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
EP2818550B1 (en) 2016-12-28
JP5890869B2 (ja) 2016-03-22
JP6306075B2 (ja) 2018-04-04
JP2016117775A (ja) 2016-06-30
WO2008141308A2 (en) 2008-11-20
EP2818550A1 (en) 2014-12-31
US20160222382A1 (en) 2016-08-04
PT2158316E (pt) 2015-07-20
DK2158316T3 (en) 2015-07-20
JP2016014070A (ja) 2016-01-28
SI2158316T1 (sl) 2015-08-31
AU2008251320B2 (en) 2013-12-19
US20110166212A1 (en) 2011-07-07
JP2017148074A (ja) 2017-08-31
US20140343132A1 (en) 2014-11-20
ES2619314T3 (es) 2017-06-26
AU2008251320A1 (en) 2008-11-20
US8741864B2 (en) 2014-06-03
EP2158316B1 (en) 2015-04-15
WO2008141308A3 (en) 2009-03-05
HK1205530A1 (en) 2015-12-18
EP3199635A1 (en) 2017-08-02
JP2014198053A (ja) 2014-10-23
HRP20150759T1 (hr) 2015-08-14
CA2723672A1 (en) 2008-11-20
JP6082796B2 (ja) 2017-02-15
JP5646320B2 (ja) 2014-12-24
EP3199635B1 (en) 2019-02-06
US20080300209A1 (en) 2008-12-04
HUE025701T2 (en) 2016-04-28
EP2158316A2 (en) 2010-03-03
US10041069B2 (en) 2018-08-07
ES2542511T3 (es) 2015-08-06
US9290762B2 (en) 2016-03-22
EP2158316A4 (en) 2011-11-09
JP2010526541A (ja) 2010-08-05
US8093225B2 (en) 2012-01-10
CA2723672C (en) 2019-09-03
US20120232131A1 (en) 2012-09-13
US7943591B2 (en) 2011-05-17

Similar Documents

Publication Publication Date Title
PL2158316T3 (pl) Ekspresja genowa oraz ból
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2069496A4 (en) SELEX AND PHOTOSELEX ENHANCED
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
ZA201200161B (en) Aximi-205 pesticidal gene and methods for its use
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
EP2240231A4 (en) MULTIFUNCTION CATHETER AND ITS USE
IL210804A (en) Benzylidenehydrazides and their uses
IL206125A0 (en) Azaindolizines and methods of use
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
GB0702931D0 (en) Skin application
PL2154144T3 (pl) Oligonukleotydy i ich zastosowanie
IL208824A0 (en) Iminopyridine derivative and use thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB0818663D0 (en) Gene regulation and its use in therapy
GB0813359D0 (en) Halfin and/or platerfin
EP2041311A4 (en) VARIANTS OF THE DPYD GENE AND THEIR USE
EP2427766A4 (en) HUMAN GENE FG01 AND ITS APPLICATIONS
GB0812734D0 (en) MEdical compsoitions and devices
EP2168951A4 (en) AZOLYLMETHYLIDENHYDRAZINE DERIVATIVE AND ITS USE
GB0720675D0 (en) Oligonucleotides and uses thereof